ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis. sBLA accepted for FDA priority review ...

賽諾菲

賽諾菲集團

<p>ACAAI：賽諾菲和再生元的 Dupixent 關鍵研究達成所有主要和次要終點，減輕過敏性真菌性鼻竇炎的症狀和體徵。sBLA 已被 FDA 接受進行優先審查</p>

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

新聞稿：ACAAI：賽諾菲和 Regeneron 的 Dupixent 關鍵研究達到了所有主要和次要終點，減少了過敏性真菌性鼻竇炎的體徵和症狀；補充生物製品許可申請被 FDA 接受為優先審查